1. Oxford Impedance Diagnostics
Low cost, high sensitivity medical diagnostics
Mr Andy Anderson
Chief Executive Officer

2. FIRST CLASS SCIENTIFIC AND MANGEMENT TEAM
Mr. Andy Anderson, Chief Executive
Over 30 years senior management experience in medical diagnostics (Astra Zeneca, Becton Dickinson, Quidel)
Former Chairman of the UK Diagnostics Trade Association (BIVDA, Elected 2001)
MD and owner of Crawford Medical Limited since 1999 – diagnostics and SME consultancy
2013/4 Business Development Director for Alzheimer’s Diagnostic Company (P/T)
Professor Jason Davis, Reader in Chemistry, University of Oxford
World renowned expert with over 140 leading peer review publications
Awarded in excess of £7 million of research council funding
Leading academic in diagnostics, molecular & medical imaging, chemical sensing, nanotechnology, bioelectronics
Professor Paulo Bueno, Research Director, Sao Paulo State University
Over 130 peer reviewed publications
Brazilian Ministry of Science Consultant
Visiting Professor University of Oxford

3. CUSTOMER NEEDS MEDICAL DIAGNOSTICS
Low cost tests for new/non-automatable analytes e.g. Breast Cancer
Rapid test development for new biomarkers e.g. Alzheimer's Disease
Highly sensitive and/or multiplex capability e.g. Insulin/CRP
Laboratory or Point of Care testing capability e.g. Dengue Fever
Proven health economic benefits e.g. Parkinson’s Disease

4. A UNIQUE PROPOSITION
A platform technology with published performance data in a number of clinical applications
Based upon over 5 years of high-quality, peer reviewed research in impedance technology
Protected by 5 exceptionally strong patents owned by Oxford University and proprietary know-how on data handling
Clinical partnerships already established driving focused test development and further research grant awards
Partnership established with an experienced device developer and working prototypes already produced

5. THE TECHNOLOGY PLATFORM
Immobilise probe to target to be measured
(e.g. antibody, DNA or peptide aptamer)
ASSAY DESIGN AND DEVELOPMENT
6-8 WEEKS
Surface that prevents any binding of serum components
SAMPLE MEASUREMENT
Target capture causes change in the impedance of the electrode solution
MEASURE CHANGE IN IMPEDANCE READER
TIME TO RESULT
10 MINUTES

6. THE EXCITING PROOF OF PRINCIPLE DATA
ASSAY WAS ABLE TO DIFFERENTIATE DISEASE FROM NORMAL
PRE - SYMPTOMATICALLY
ASSAY CORRELATES WITH LAB ELISA ASSAY
Chemical Science , 3 (12) ,
Analytical Chem., 2013, 85,
EARLY STAGE PARKINSON’S DISEASE DIAGNOSTIC TEST
THE MOST SENSITIVE INSULIN ASSAY EVER PRODUCED

7. New biomarker assay design and measurement projects
PARALLEL STRATEGIES TO REDUCE RISK and GAIN EARLY REVENUE
Develop and launch assays for breast cancer, dengue fever and Parkinson’s disease
New biomarker assay design and measurement projects
Establish platform credentials
Generate high revenues/value
Longer time frame
Early revenues
Clinical trial support
Establish pharma network/collaborations

8. A S Y D E V L OPME N T Breast Cancer Dengue Fever Parkinson’s Disease
Diagnosis via mammography and invasive biopsy
Up to 30% cases missed
Established companion diagnostic – HER2 (HercepTestTM) and Herceptin
ANNUAL SALES POTENTIAL
£300 MILLION
Dengue Fever
Difficult to differentiate from other viral diseases
Infects 50 to 528 million people worldwide a year, leading to half a million hospitalizations
12 countries in Asia see 3 million infections and 6,000 deaths per year
No commercial competitor
ANNUAL SALES POTENTIAL
£550 MILLION M A R K E T P O N I L
Parkinson’s Disease
Currently diagnosed by symptoms appearing
Condition develops years before symptoms appear
Therapy development hampered by lack of good biomarker
>400 therapy trials underway
ANNUAL SALES POTENTIAL
£100 MILLION
We should try to say something about Dengue if we can.
Also, can we explain if asked what the likely/proposed:
route to market would be
Clinical care pathway – i.e. who benefits, what current provision is etc..
OUR PRODUCTS
COMPANION DIAGNOSTIC HER 2 ASSAY
LOW COST POINT OF CARE TEST
EARLY STAGE DIAGNOSTIC TEST

9. SECOND STAGE INVESTMENT FOR CLINICAL TRIALS AND PRODUCT LAUNCHES
THE FINANCES AND DEVELOPMENT TARGET
2015
2016
2017
2018
2019
2020
Grand Total
Expenses
700,000
775,000
2,195,000
2,375,000
1,845,000
1,695,000
9,435,000
Sales
100,000
1,375,000
1,800,000
2,250,000
5,225,000
Profit
-700,000
-775,000
-2,095,000
-1,000,000
-45,000
555,000
INVESTMENT OF £1.4 MILLION REQUIRED TO SET UP A COMMERCIAL DEVELOPMENT and SERVICE LABORATORY
SECOND STAGE INVESTMENT FOR CLINICAL TRIALS AND PRODUCT LAUNCHES
FIRST GOAL – CONVERT MANUAL SLOW ASSAY USING EXPENSIVE ELECTRODES TO SEMI-AUTOMATED CHIP SYSTEM

10. SUMMARY
Summary
Unique low risk investment opportunity in platform and assay developments
High-profile assay targets with global sales potential
Highly experienced business and science team
Existing clinical data and working assays
Leading clinical collaborators
Additional development and expansion possibilities in Brazil
Trade sales potential generated during development phases

11. CONTACT INFORMATION
Andy Anderson
CEO
Oxford Impedance Diagnostics
M: +44 (0)
Office
Professor Jason Davis
Founder and CSO
Oxford Impedance Diagnostics